JP2013536157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536157A5 JP2013536157A5 JP2013512926A JP2013512926A JP2013536157A5 JP 2013536157 A5 JP2013536157 A5 JP 2013536157A5 JP 2013512926 A JP2013512926 A JP 2013512926A JP 2013512926 A JP2013512926 A JP 2013512926A JP 2013536157 A5 JP2013536157 A5 JP 2013536157A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- amino acid
- acid sequence
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 239000012830 cancer therapeutic Substances 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 229940022399 cancer vaccine Drugs 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000006311 Cyclin D1 Human genes 0.000 claims 1
- 108010058546 Cyclin D1 Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000003203 everyday effect Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35073110P | 2010-06-02 | 2010-06-02 | |
| US61/350,731 | 2010-06-02 | ||
| GB201009222A GB201009222D0 (en) | 2010-06-02 | 2010-06-02 | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| GB1009222.9 | 2010-06-02 | ||
| PCT/EP2011/059121 WO2011151403A1 (en) | 2010-06-02 | 2011-06-01 | Improved cancer therapy based on tumor associated antigens derived from cyclin d1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013536157A JP2013536157A (ja) | 2013-09-19 |
| JP2013536157A5 true JP2013536157A5 (enExample) | 2014-07-17 |
Family
ID=42471037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013512926A Pending JP2013536157A (ja) | 2010-06-02 | 2011-06-01 | サイクリンｄ１由来腫瘍関連抗原に基づくがん治療法の改良 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9056069B2 (enExample) |
| EP (1) | EP2575850A1 (enExample) |
| JP (1) | JP2013536157A (enExample) |
| KR (1) | KR20130089175A (enExample) |
| CN (1) | CN102971003A (enExample) |
| AU (1) | AU2011260277B2 (enExample) |
| BR (1) | BR112012030479A2 (enExample) |
| CA (1) | CA2793601A1 (enExample) |
| EA (1) | EA201291195A1 (enExample) |
| GB (1) | GB201009222D0 (enExample) |
| MX (1) | MX2012013998A (enExample) |
| MY (1) | MY162741A (enExample) |
| NZ (1) | NZ601677A (enExample) |
| PH (1) | PH12012501898A1 (enExample) |
| SG (1) | SG185353A1 (enExample) |
| UA (1) | UA110473C2 (enExample) |
| WO (1) | WO2011151403A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| CN103848891B (zh) * | 2012-11-30 | 2015-09-09 | 北京市结核病胸部肿瘤研究所 | Ccnd1自身抗体识别的抗原多肽 |
| JP6497691B2 (ja) * | 2013-02-05 | 2019-04-10 | 日東電工株式会社 | 粘膜投与用ｗｔ１ペプチド癌ワクチン組成物 |
| US10449144B2 (en) * | 2013-02-05 | 2019-10-22 | Nitto Denko Corporation | WT1 peptide cancer vaccine composition for transdermal administration |
| HRP20192262T1 (hr) | 2013-08-05 | 2020-03-06 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) |
| TWI819228B (zh) * | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| CN104017051B (zh) * | 2014-06-23 | 2016-08-17 | 深圳市华中生物药械有限公司 | 一种Cyclin D 蛋白抑制剂多肽及其应用 |
| GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
| CA2989483A1 (en) | 2015-06-19 | 2016-12-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers |
| GB201511191D0 (en) * | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
| HK1254866A1 (zh) | 2015-06-25 | 2019-07-26 | Immatics Biotechnologies Gmbh | 用於骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物 |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| MA42294B1 (fr) | 2015-07-01 | 2020-11-30 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
| CN107912043B (zh) | 2015-07-06 | 2022-02-18 | 伊玛提克斯生物技术有限公司 | 用于食管癌和其他癌症免疫治疗的新型肽和肽组合物 |
| GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| CN114028549A (zh) | 2016-02-19 | 2022-02-11 | 伊玛提克斯生物技术有限公司 | 用于nhl和其他癌症免疫治疗的新型肽和肽组合物 |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| MA54832A (fr) * | 2016-03-01 | 2021-12-01 | Immatics Biotechnologies Gmbh | Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| CN112553336B (zh) * | 2020-12-17 | 2023-07-21 | 兰州大学 | Snp在乳腺癌化疗耐药性检测领域的应用及其检测试剂盒 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| DE10225144A1 (de) * | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| EP1660636A4 (en) | 2003-08-26 | 2009-07-01 | Univ Texas | VACCINES AGAINST CANCER |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| DE602004019215D1 (de) | 2004-10-02 | 2009-03-12 | Immatics Biotechnologies Gmbh | Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden |
| PL1760088T3 (pl) | 2005-09-05 | 2008-10-31 | Immatics Biotechnologies Gmbh | Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA) |
| PL1760089T3 (pl) * | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| WO2009015841A1 (en) | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
| CA2991175A1 (en) * | 2007-11-01 | 2009-05-07 | Mayo Foundation For Medical Education And Research | Hla-dr binding peptides and their uses |
| PT2119726E (pt) * | 2008-05-14 | 2015-03-30 | Immatics Biotechnologies Gmbh | Novos e poderosos peptídeos para mhc classe ii derivados de survinina e neurocano |
| JP2012520073A (ja) * | 2009-03-10 | 2012-09-06 | ベイラー リサーチ インスティテュート | 抗原提示細胞ターゲティングワクチン |
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
-
2010
- 2010-06-02 GB GB201009222A patent/GB201009222D0/en not_active Ceased
-
2011
- 2011-06-01 CN CN2011800266565A patent/CN102971003A/zh active Pending
- 2011-06-01 CA CA2793601A patent/CA2793601A1/en not_active Abandoned
- 2011-06-01 MX MX2012013998A patent/MX2012013998A/es active IP Right Grant
- 2011-06-01 KR KR1020127034291A patent/KR20130089175A/ko not_active Ceased
- 2011-06-01 EP EP11722825.4A patent/EP2575850A1/en not_active Withdrawn
- 2011-06-01 BR BR112012030479A patent/BR112012030479A2/pt not_active IP Right Cessation
- 2011-06-01 US US13/150,785 patent/US9056069B2/en active Active
- 2011-06-01 AU AU2011260277A patent/AU2011260277B2/en not_active Ceased
- 2011-06-01 US US13/643,043 patent/US9023803B2/en active Active
- 2011-06-01 UA UAA201210089A patent/UA110473C2/uk unknown
- 2011-06-01 WO PCT/EP2011/059121 patent/WO2011151403A1/en not_active Ceased
- 2011-06-01 JP JP2013512926A patent/JP2013536157A/ja active Pending
- 2011-06-01 PH PH1/2012/501898A patent/PH12012501898A1/en unknown
- 2011-06-01 MY MYPI2012700611A patent/MY162741A/en unknown
- 2011-06-01 EA EA201291195A patent/EA201291195A1/ru unknown
- 2011-06-01 NZ NZ60167711A patent/NZ601677A/en not_active IP Right Cessation
- 2011-06-01 SG SG2012065918A patent/SG185353A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536157A5 (enExample) | ||
| Lei et al. | Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy | |
| Frega et al. | Trial Watch: experimental TLR7/TLR8 agonists for oncological indications | |
| Chakraborty et al. | Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy | |
| US12214048B2 (en) | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine | |
| Abdou et al. | Advances in engineering local drug delivery systems for cancer immunotherapy | |
| Krieg | Development of TLR9 agonists for cancer therapy | |
| JP7181880B2 (ja) | 免疫療法のためのコア／シェル構造プラットホーム | |
| JP6993240B2 (ja) | 結腸直腸癌を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体 | |
| Berger et al. | Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma | |
| Lin et al. | Therapeutic hpv DNA vaccines | |
| JP5239041B2 (ja) | 癌の治療剤 | |
| ES2460899T3 (es) | Inmunoterapia basada en células cancerosas alógenas | |
| JP2019528693A (ja) | 癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体 | |
| ES2900262T3 (es) | Un medicamento para el uso en un método para inducir o extender una respuesta inmunitaria citotóxica celular | |
| Garnett-Benson et al. | Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities | |
| Goldstein et al. | A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors | |
| Hu et al. | Highly enhanced antitumor immunity by a three-barreled strategy of the l-arginine-promoted nanovaccine and gene-mediated PD-L1 blockade | |
| Speir et al. | Engaging natural killer T cells as ‘Universal Helpers’ for vaccination | |
| Lin et al. | The role of peptide and DNA vaccines in myeloid leukemia immunotherapy | |
| JP6311094B2 (ja) | 医薬 | |
| U'ren et al. | Vaccination with liposome–DNA complexes elicits enhanced antitumor immunity | |
| Jang et al. | Dendritic cells stimulated with outer membrane protein A (OmpA) of Salmonella typhimurium generate effective anti-tumor immunity | |
| JP2012506235A5 (enExample) | ||
| WO2017062708A1 (en) | T cell delivery of mda-7/il-24 to improve therapeutic eradication of cancer and generate protective antitumor immunity |